Foster City, CA-based SciClone Pharmaceuticals ($SCLN) has come up empty-handed again after concluding its latest Phase IIb trial for SCV-07 should be shuttered after proving ineffective for oral mucositis, a common side effect for cancer patients. Investigators earlier tried and failed to demonstrate the treatment might be effective for hepatitis C. SciClone said on Friday it is washing its hands of the drug as it shifts all of its focus to China's specialty drug market. Release